Ansofaxine Hydrochloride | Zendy

Vjekoslav Peitl | Zendy; Darko Vlahović | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ansofaxine Hydrochloride

Author(s) -

Vjekoslav Peitl,

Darko Vlahović

Publication year - 2020

Publication title -

archives of psychiatry research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.117

H-Index - 8

eISSN - 2671-2008

pISSN - 2671-1079

DOI - 10.20471/may.2020.57.01.09

Subject(s) - prodrug , reuptake inhibitor , reuptake , dopamine , pharmacology , norepinephrine , norepinephrine transporter , chemistry , hydrochloride , serotonin , medicine , biochemistry , receptor

Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor that inhibits serotonin, dopamine and norepinephrine reuptake. This novel triple reuptake inhibitor is a carboxylic acid ester prodrug of desvenlafaxine. It is currently under development for the treatment of major depressive disorder - a frequent and heterogeneous disorder induced by a complex pattern of genetic, epigenetic, developmental, and environmental factors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research